M
Malcolm J. Moore
Researcher at Princess Margaret Cancer Centre
Publications - 238
Citations - 45832
Malcolm J. Moore is an academic researcher from Princess Margaret Cancer Centre. The author has contributed to research in topics: Gemcitabine & Cancer. The author has an hindex of 64, co-authored 231 publications receiving 42222 citations. Previous affiliations of Malcolm J. Moore include University Health Network & Ontario Institute for Cancer Research.
Papers
More filters
Journal ArticleDOI
Phase II study of erlotinib (OSI-774) in patients with metastatic colorectal cancer
Carol A. Townsley,Pierre Major,Lillian L. Siu,Janet Dancey,Eric Chen,Gregory R. Pond,Trudey Nicklee,James Ho,David W. Hedley,Ming-Sound Tsao,Malcolm J. Moore,Amit M. Oza +11 more
TL;DR: Erlotinib was well tolerated with the most common toxicities being rash and diarrhoea and correlative studies showed a reduction in phosphorylated EGFR and ERK in tumour tissue post-treatment.
Journal Article
Differential sensitivity of various pediatric cancers and squamous cell carcinomas to lovastatin-induced apoptosis: therapeutic implications.
Jim Dimitroulakos,Lily Y. Ye,Mark Benzaquen,Malcolm J. Moore,Suzanne Kamel-Reid,Melvin H. Freedman,Herman Yeger,Linda Z. Penn +7 more
TL;DR: It is demonstrated that the apoptotic properties of lovastatin are triggered by the open ring acid form that is a potent inhibitor of HMG-CoA reductase activity.
Journal ArticleDOI
Use of palliative end points to evaluate the effects of mitoxantrone and low-dose prednisone in patients with hormonally resistant prostate cancer.
Malcolm J. Moore,David Osoba,K. C. Murphy,Ian F. Tannock,A Armitage,B. Findlay,C. M. L. Coppin,Alan J. Neville,Peter Venner,J. J. Wilson +9 more
TL;DR: Mitoxantrone with low-dose prednisone is a well-tolerated treatment regimen that has some beneficial effects on disease-related symptoms and quality of life for patients with advanced prostate cancer.
Journal ArticleDOI
The Desire for Hastened Death in Patients with Metastatic Cancer
Gary Rodin,Camilla Zimmermann,Anne Rydall,Jennifer M. Jones,Frances A. Shepherd,Malcolm J. Moore,Martin Fruh,Allan Donner,Lucia Gagliese +8 more
TL;DR: The relative absence of a strong DHD in this sample suggests that the will to live tends to be preserved in cancer patients prior to the end of life, in spite of significant emotional and physical suffering.
Journal ArticleDOI
Molecular Predictors of Outcome in a Phase 3 Study of Gemcitabine and Erlotinib Therapy in Patients With Advanced Pancreatic Cancer: National Cancer Institute of Canada Clinical Trials Group Study PA.3
Gilda da Cunha Santos,Neesha C. Dhani,Dongsheng Tu,Kayu Chin,Olga Ludkovski,Suzanne Kamel-Reid,Suzanne Kamel-Reid,Jeremy A. Squire,Wendy R. Parulekar,Malcolm J. Moore,Malcolm J. Moore,Ming-Sound Tsao,Ming-Sound Tsao +12 more
TL;DR: Mutation status of the v‐Ki‐ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) and EGFR gene copy number (GCN) were evaluated as predictive markers in 26% of patients who had tumor samples available for analysis.